Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2025 · 10-Q
Revenue$30.48M$30.48M+37.6% vs Q1 2024 Net Income$5.06M$5.06MN/M vs Q1 2024 EPS Diluted$0.06$0.06N/M vs Q1 2024 Gross Profit$19,331,000+43.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow$7,883,000+2,572.2% Margins · derivedGross margin63.4%+2.7 pt vs Q1 2024
Operating margin15.7%+19.0 pt vs Q1 2024
Net margin16.6%+18.8 pt vs Q1 2024
ended Mar 31, 2025 · filed May 7, 2025 · 37 d after period end